Cleerly
Cleerly is an American digital healthcare company whose FDA-cleared, AI-driven CCTA platform analyzes coronary plaque, stenosis and ischemia to personalize heart attack prevention.
Last updated September 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Cleerly is an American digital healthcare company on a mission to eliminate heart attacks by establishing a new standard of precision heart care. Its core offering is an artificial-intelligence-enabled coronary CT angiography (CCTA) solution that provides comprehensive, accurate and trackable insights into coronary artery disease (CAD), helping clinicians personalize heart attack prevention. The platform leverages machine learning variables to analyze and characterize plaque, calculate stenosis and detect likely ischemia in specific vessels, supporting comprehensive phenotyping of coronary artery disease from advanced noninvasive CT imaging. The company positions its technology as clinically validated rather than merely convenient. Cleerly states that its approach is grounded in science and based on millions of images from over 40,000 patients, and that its accuracy is demonstrated across multiple peer-reviewed, multicenter clinical studies. These include the prospective, multicenter CREDENCE trial, in which Cleerly ISCHEMIA demonstrated higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing, referenced to 868 invasive fractional flow reserve (FFR) measurements as the gold standard for determining ischemia. In a post-hoc analysis of the PACIFIC study, Cleerly ISCHEMIA was compared to FFRCT, 15O-H2O PET and SPECT for predicting invasive FFR≤0.8; on a per-patient basis Cleerly ISCHEMIA, FFRCT and PET performed similarly and outperformed SPECT, and Cleerly ISCHEMIA was the only non-invasive ischemia test prognostic of future MACE events in multivariate analysis. Cleerly also cites published performance against invasive gold standards for plaque quantification (intravascular ultrasound, IVUS) and plaque composition (near-infrared spectroscopy, NIRS). Cleerly serves the coronary care pathway through distinct audiences. For healthcare providers, it offers a clinical workflow that brings AI-driven CCTA analysis into cardiac care assessments, with the aim of empowering better treatment decisions and improving diagnostic testing and patient outcomes. For payors and providers, the company highlights commercial insurance coverage and a Category I code, signaling that its solution is being integrated into reimbursement pathways. For patients, Cleerly frames its solution as a way to take control of heart health, noting that coronary artery disease accounts for more than 900,000 fatalities a year. Cleerly is described in public data as an American digital healthcare company. It operates in the United States and is led by a world-class clinical and technical team, according to its own materials. The company offers software demonstrations to organizations interested in adopting its AI-driven CCTA analysis, and maintains a list of clinical publications. Its stated mission is to establish the global adoption of a new standard of precision heart care for everyone.
History
Cleerly is an American digital healthcare company focused on precision heart care. Public data describes it as an American digital healthcare company, and its own materials state that it is on a mission to eliminate heart attacks by creating a new standard of care for heart disease. The company built its approach around artificial intelligence applied to advanced noninvasive CT imaging, specifically coronary CT angiography (CCTA), to support comprehensive phenotyping of coronary artery disease. Cleerly states that its approach is grounded in science and based on millions of images from over 40,000 patients. Its technology is supported by a large body of clinical evidence, with accuracy demonstrated across multiple peer-reviewed, multicenter clinical studies. Among these, the prospective, multicenter CREDENCE trial showed that Cleerly ISCHEMIA achieved higher diagnostic accuracy and area under the curve compared to FFRCT and stress testing, referenced to 868 invasive fractional flow reserve (FFR) measurements, the gold standard for determining ischemia. In a post-hoc analysis of the PACIFIC study, Cleerly ISCHEMIA was compared to FFRCT, 15O-H2O PET and SPECT to predict invasive FFR≤0.8; on a per-patient basis Cleerly ISCHEMIA, FFRCT and PET performed similarly and outperformed SPECT, and Cleerly ISCHEMIA was the only non-invasive ischemia test prognostic of future MACE events in multivariate analysis. Cleerly also cites published performance against invasive gold standards for plaque quantification (intravascular ultrasound, IVUS) and plaque composition (near-infrared spectroscopy, NIRS). The company has developed a clinical workflow for healthcare providers and markets its solution to payors and providers, highlighting new commercial insurance coverage and a Category I code. It also addresses patients directly, noting that coronary artery disease accounts for more than 900,000 fatalities a year. Cleerly offers software demonstrations to organizations and maintains a list of clinical publications. Its stated mission is to establish the global adoption of a new standard of precision heart care for everyone.
Products and positioning
A clinically validated, FDA-cleared AI platform for precision heart care that aims to eliminate heart attacks by setting a new standard for coronary artery disease assessment.
Cleerly ISCHEMIA
An AI-driven CCTA-based ischemia assessment demonstrated in the CREDENCE and PACIFIC trials.
AI-enabled CCTA solution
Provides comprehensive, accurate and trackable insights to personalize heart attack prevention.
Recent events
Cleerly secures $43 million in Series B investment[4]
Reported:
Cleerly’s Series B funding round brought in $43 million in new investments. The round was led by Vensana Capital, with additional investors named in the report.
Cleerly launches AI-powered cardiac imaging platform[4]
Reported:
Cleerly launched an AI-powered imaging platform that analyzes non-invasive CT angiography scans and coronary plaque to assess heart attack risk.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/cleerly · Editorial policy · How profiles are compiled